Serina Therapeutics shares jumped nearly 35% after the FDA cleared its IND application for SER-252, advancing plans for a Phase 1b trial in advanced Parkinson’s disease.
Importance Rank:
1
Serina Therapeutics shares jumped nearly 35% after the FDA cleared its IND application for SER-252, advancing plans for a Phase 1b trial in advanced Parkinson’s disease.
© MegaHoot, LLC. All Rights Reserved | media at hootdex.com | Privacy Policy | Risk Disclosure | Legal Disclaimer | TOS | AML/KYC
